Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 20/20 | 1.00 |
| ▸ | ITGB1 | P05556 | 19/20 | 1.00 |
| ▸ | ITGB7 | P26010 | 17/20 | 1.00 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19235765 | 1.00 | ITGA4 (1.00) | ITGA4ITGB1ITGB7ITGA2 | |
| SCHEMBL6238341 | 0.91 | ITGA4 (0.83) | ITGA4ITGB1ITGB7ITGA2 | |
| SCHEMBL27503936 | 0.88 | ITGA4 (0.79) | ITGA4ITGB1ITGB7 | |
| SCHEMBL27503937 | 0.88 | ITGA4 (0.79) | ITGA4ITGB1ITGB7 | |
| SCHEMBL4892223 | 0.87 | ITGA4 (0.77) | ITGA4ITGB1ITGB7ITGA2 | |
| SCHEMBL4886949 | 0.87 | ITGA4 (1.00) | ITGA4ITGB1ITGB7ITGA2 | |
| SCHEMBL5164939 | 0.85 | ITGA4 (0.81) | ITGA4ITGB1ITGB7ITGA2 | |
| SCHEMBL4892779 | 0.83 | ITGA4 (1.00) | ITGA4ITGB1ITGB7 | |
| SCHEMBL18589274 | 0.80 | ITGB1 (1.00) | ITGA4ITGB1ITGB7 | |
| SCHEMBL5160282 | 0.80 | ITGB1 (1.00) | ITGA4ITGB1ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6916933-B2 | 4-pyridinyl-n-acyl-l-phenylalanines | HOFFMAN-LA ROCHE INC. (US) | 2005-07-12 | — | — | US | claimed |
| EP-1244625-B1 | 4-PYRIDINYL-N-ACYL-L-PHENYLALANINES | HOFFMANN LA ROCHE (CH) | 2005-06-15 | — | — | EP | claimed |
| US-20040127706-A1 | 4-Pyridinyl-n-acyl-l-phenylalanines | KAPLAN GERALD LEWIS (US) | 2004-07-01 | — | — | US | claimed |
| EP-1244625-A1 | 4-PYRIDINYL-N-ACYL-L-PHENYLALANINES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-10-02 | — | — | EP | claimed |
| US-20020133015-A1 | 4-pyridinyl-N-acyl-L-phenylalanines | KAPLAN GERALD LEWIS (US) | 2002-09-19 | — | — | US | claimed |
| WO-2001042215-A1 | 4-PYRIDINYL-N-ACYL-L-PHENYLALANINES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-06-14 | — | — | WO | claimed |
| US-10562898-B2 | Substituted benzenesulfonamides as inhibitors of alpha-4 beta-7 integrin activity | EA PHARMA CO., LTD. (JP) | 2020-02-18 | — | — | US | disclosed |
| US-20190040059-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | EA PHARMA CO., LTD. (JP) | 2019-02-07 | — | — | US | disclosed |
| WO-2017135472-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | ＥＡファーマ株式会社 | 2017-08-10 | — | — | WO | disclosed |
| WO-2017135471-A1 | INTEGRIN α4β7 INHIBITOR | ＥＡファーマ株式会社 | 2017-08-10 | — | — | WO | disclosed |
| US-20140051655-A1 | METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH ALPHA-4 INHIBITORY COMPOUNDS | ELAN PHARMACEUTICALS, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8410115-B2 | Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds | ELAN PHARMACEUTICALS, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| EP-2007392-A2 | METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH ALPHA-4 INHIBITORY COMPOUNDS | ELAN PHARMACEUTICALS, INC. (US) | 2008-12-31 | — | — | EP | disclosed |
| US-6916933-B2 | 4-pyridinyl-n-acyl-l-phenylalanines | HOFFMAN-LA ROCHE INC. (US) | 2005-07-12 | — | — | US | disclosed |
| EP-1244625-B1 | 4-PYRIDINYL-N-ACYL-L-PHENYLALANINES | HOFFMANN LA ROCHE (CH) | 2005-06-15 | — | — | EP | disclosed |
| US-20040127706-A1 | 4-Pyridinyl-n-acyl-l-phenylalanines | KAPLAN GERALD LEWIS (US) | 2004-07-01 | — | — | US | disclosed |
| EP-1244625-A1 | 4-PYRIDINYL-N-ACYL-L-PHENYLALANINES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-10-02 | — | — | EP | disclosed |
| US-20020133015-A1 | 4-pyridinyl-N-acyl-L-phenylalanines | KAPLAN GERALD LEWIS (US) | 2002-09-19 | — | — | US | disclosed |
| US-6388084-B1 | 4-pyridinyl-n-acyl-l-phenylalanines | HOFFMANN-LA ROCHE INC. | 2002-05-14 | — | — | US | disclosed |
| WO-2001042215-A1 | 4-PYRIDINYL-N-ACYL-L-PHENYLALANINES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051655-A1 | METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH ALPHA-4 INHIBITORY COMPOUNDS | IL4, PSMA4, SCN4A | ITGA4 27/4885ITGB1 277/4885ITGB7 464/4885 |
| US-10562898-B2 | Substituted benzenesulfonamides as inhibitors of alpha-4 beta-7 integrin activity | ITGB4, ITGB7, ITGA4 | ITGA4 3/4885ITGB1 4/4885ITGB7 2/4885 |
| US-20190040059-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | ITGB4, ITGB5, ITGA4 | ITGA4 3/4885ITGB1 8/4885ITGB7 14/4885 |
| US-20040127706-A1 | 4-Pyridinyl-n-acyl-l-phenylalanines | VCAM1, ICAM1, SELPLG | ITGA4 8/4885ITGB1 13/4885ITGB7 99/4885 |
| US-20020133015-A1 | 4-pyridinyl-N-acyl-L-phenylalanines | VCAM1, ICAM1, SELPLG | ITGA4 8/4885ITGB1 13/4885ITGB7 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.